Workflow
ARS Pharmaceuticals Secures Up to $250 Million Loan Facility with RA Capital Management and OMERS Life Sciences to Accelerate U.S. Commercialization of neffy®
ARS PharmaceuticalsARS Pharmaceuticals(US:SPRY) Globenewswire·2025-09-29 20:05

Initial 100milliontermloantopropelmarketsharegrowthintheU.S.SANDIEGO,Sept.29,2025(GLOBENEWSWIRE)−−ARSPharmaceuticals,Inc.(Nasdaq:SPRY),acommercial−stagebiopharmaceuticalcompanydedicatedtoempoweringat−riskpatientsandtheircaregiverstobetterprotectpatientsfromallergicreactionsthatcouldleadtoanaphylaxis,todayannouncedithasenteredintoaseniorsecuredtermloanfacilityofupto100 million term loan to propel market share growth in the U.S. SAN DIEGO, Sept. 29, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a commercial-stage biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis, today announced it has entered into a senior secured term loan facility of up to 250 million with an affiliate of RA Capital Management (RA Capital), the compan ...